$ENTX News

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting

Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting

Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting

Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise

Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11

Cantor Fitzgerald Initiates Coverage On Entera Bio with Overweight Rating

Leerink Partners Initiates Coverage On Entera Bio with Outperform Rating, Announces Price Target of $9

Correction: Entera to Participate in Upcoming Fall Investor Conferences

Entera to Participate in Upcoming Fall Investor Conferences

Entera Bio Files Prospectus For Resale Of Up To 134,803,910 Ordinary Shares By Selling Shareholders From July Private Placement

Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement

Entera Bio shares slip as Q2 loss comes in wider than expected

Entera Bio (NASDAQ:ENTX) Slides on Wider Q2 Loss Despite FDA Phase 3 Alignment and $275M Cash Raise

Entera Announces Second Quarter 2026 Financial Results and Business Updates

Entera Bio Intends To File Ind For EB612 In First Half Of 2027; EB613 Phase 3 Study Initiation Planned For Late 2026, Topline Data Anticipated In Second Half 2028

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting

Entera Bio Announces That Post-Hoc Data From Its Phase 2 Clinical Trial Of EB613Has Been Selected For Two Presentations At The American Society For Bone And Mineral Research Annual Meeting

Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference

Entera Bio Rebounds As Investors Balance Phase 3 Funding Against Dilution Risk